Literature DB >> 19259304

Perforation and Stage-II Colon Cancer: Is it Always High Risk?

Charles D Blanke1.   

Abstract

Entities:  

Year:  2008        PMID： 19259304      PMCID： PMC2630827     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  1 in total

1.  Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.

Authors:  John L Marshall; Daniel G Haller; Aimery de Gramont; Howard S Hochster; Heinz-Josef Lenz; Jaffer A Ajani; Richard M Goldberg
Journal:  Gastrointest Cancer Res       Date:  2007-07
  1 in total
  4 in total

1.  Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.

Authors:  Leili Ran; Inna Sirota; Zhen Cao; Devan Murphy; Yuedan Chen; Shipra Shukla; Yuanyuan Xie; Michael C Kaufmann; Dong Gao; Sinan Zhu; Ferdinando Rossi; John Wongvipat; Takahiro Taguchi; William D Tap; Ingo K Mellinghoff; Peter Besmer; Cristina R Antonescu; Yu Chen; Ping Chi
Journal:  Cancer Discov       Date:  2015-01-08       Impact factor: 39.397

2.  Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.

Authors:  Patrick Chun; Zev A Wainberg
Journal:  Gastrointest Cancer Res       Date:  2009-09

3.  Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.

Authors:  Ping Chi; Li-Xuan Qin; Bastien Nguyen; Ciara M Kelly; Sandra P D'Angelo; Mark A Dickson; Mrinal M Gounder; Mary L Keohan; Sujana Movva; Benjamin A Nacev; Evan Rosenbaum; Katherine A Thornton; Aimee M Crago; Sam Yoon; Gary Ulaner; Randy Yeh; Moriah Martindale; Haley T Phelan; Matthew D Biniakewitz; Sarah Warda; Cindy J Lee; Michael F Berger; Nikolaus D Schultz; Samuel Singer; Sinchun Hwang; Yu Chen; Cristina R Antonescu; William D Tap
Journal:  J Clin Oncol       Date:  2022-01-18       Impact factor: 44.544

4.  Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma.

Authors:  Peter F Lenehan; Lisa A Boardman; Douglas Riegert-Johnson; Giovanni De Petris; David W Fry; Jeanne Ohrnberger; Eugene R Heyman; Brigitte Gerard; Arpit A Almal; William P Worzel
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.